SF3B1 and myelodysplastic syndrome: Although SF3B1 mutations have been shown to predict better OS in MDS patients,[3, 19, 23, 24] we found the mutation was associated with a lower CR rate (Supplementary Table 2A) and shorter survival in de novo AML patients (Supplementary Figure 1A, B).